1-(3-(2-(1-isopropyl-1H-1,2,4-triazol-5-yl)-4,5-dihydrobenzo[b]pyrazolo[1,5-d][1,4]oxazepin-9-yl)azetidin-1-yl)ethanone | 1282512-00-8

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 1-(3-(2-(1-isopropyl-1H-1,2,4-triazol-5-yl)-4,5-dihydrobenzo[b]pyrazolo[1,5-d][1,4]oxazepin-9-yl)azetidin-1-yl)ethanone
• 英文别名: 1-[3-[2-(2-propan-2-yl-1,2,4-triazol-3-yl)-4,5-dihydropyrazolo[5,1-d][1,5]benzoxazepin-9-yl]azetidin-1-yl]ethanone
• CAS: 1282512-00-8
• 化学式: C₂₁H₂₄N₆O₂
• 分子量: 392.461
• InChiKey: UNNREFBRDGXROE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  78.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  9-(azetidin-3-yl)-2-(1-isopropyl-1H-1,2,4-triazol-5-yl)-4,5-dihydrobenzo[b]pyrazolo[1,5-d][1,4]oxazepine 、 乙酸酐 以to give 149 as a white solid的产率得到1-(3-(2-(1-isopropyl-1H-1,2,4-triazol-5-yl)-4,5-dihydrobenzo[b]pyrazolo[1,5-d][1,4]oxazepin-9-yl)azetidin-1-yl)ethanone
  参考文献：
  名称：

  Benzoxazepin PI3K inhibitor compounds and methods of use

  摘要：

  公式I中的苯并噁唑环化合物，包括立体异构体、几何异构体、互变异构体、溶剂化物、代谢物和其药学上可接受的盐，其中：Z1是CR1或N；Z2是CR2或N；Z3是CR3或N；Z4是CR4或N；而B是咪唑环、咪唑啉环或三唑环融合到苯并噁唑环上，用于抑制脂质激酶包括p110 alpha和PI3K的其他亚型，以及治疗由脂质激酶介导的癌症等疾病。公开了使用公式I中的化合物进行哺乳动物细胞中的体外、原位和体内诊断、预防或治疗此类疾病或相关病理条件的方法。

  公开号：

  US08785626B2

文献信息

• BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
  申请人：Blaquiere Nicole

  公开号：US20110076292A1

  公开（公告）日：2011-03-31

  Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z 1 is CR 1 or N; Z 2 is CR 2 or N; Z 3 is CR 3 or N; Z 4 is CR 4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  方程式I中的苯并噁唑啉化合物，包括立体异构体、几何异构体、互变异构体、溶剂合物、代谢物及其药用可接受盐，其中：Z1为CR1或N；Z2为CR2或N；Z3为CR3或N；Z4为CR4或N；B为与苯并噁唑啉环融合的吡唑基、咪唑基或三唑基环，用于抑制脂质激酶包括p110 alpha和PI3K的其他同系物，并用于治疗由脂质激酶介导的癌症等疾病。公开了使用方程式I中的化合物在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗此类疾病或相关病理条件的方法。
• [EN] BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS DE BENZOXAZÉPINE INHIBITEURS DE PI3K ET LEURS PROCÉDÉS D'UTILISATION
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011036280A1

  公开（公告）日：2011-03-31

  The invention relates to benzoxazepin compounds of Formula (I) including stereoisomers, geometric isomers, tautomers, or pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring which compounds have anti-cancer activity, and more specifically, inhibit PI3 kinase activity.

  本发明涉及公式（I）的苯并噁唑烷化合物，包括立体异构体，几何异构体，互变异构体或其药学上可接受的盐，其中：Z1为CR1或N；Z2为CR2或N；Z3为CR3或N；Z4为CR4或N；B为吡唑基，咪唑基或三唑基环，这些化合物具有抗癌活性，更具体地抑制PI3激酶活性。
• Benzoxazepin P13K inhibitor compounds and methods of use
  申请人：F. Hoffman-La Roche AG

  公开号：US08242104B2

  公开（公告）日：2012-08-14

  Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式I中的苯并噁唑环化合物，包括立体异构体、几何异构体、互变异构体、溶剂化物、代谢物和其药学上可接受的盐，其中：Z1是CR1或N；Z2是CR2或N；Z3是CR3或N；Z4是CR4或N；B是咪唑环、咪唑啉环或三唑啉环融合到苯并噁唑环上，用于抑制脂质激酶，包括p110α和其他PI3K的亚型，并用于治疗由脂质激酶介导的癌症等疾病。还公开了使用公式I中化合物在哺乳动物细胞中进行体外、原位和体内诊断、预防或治疗此类疾病或相关病理条件的方法。
• BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2483278B1

  公开（公告）日：2013-12-25
• US8242104B2
  申请人：——

  公开号：US8242104B2

  公开（公告）日：2012-08-14